197 related articles for article (PubMed ID: 7789481)
1. Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus.
Zahm JM; Girod de Bentzmann S; Deneuville E; Perrot-Minnot C; Dabadie A; Pennaforte F; Roussey M; Shak S; Puchelle E
Eur Respir J; 1995 Mar; 8(3):381-6. PubMed ID: 7789481
[TBL] [Abstract][Full Text] [Related]
2. [Effect of rhDNase on rheologic properties and transport capacity of mucus in cystic fibrosis].
Puchelle E; Zahm JM
Arch Pediatr; 1995 Jul; 2(7):670-3. PubMed ID: 7663658
[TBL] [Abstract][Full Text] [Related]
3. Effects of rhDNase on purulent airway secretions in chronic bronchitis.
Puchelle E; Zahm JM; de Bentzmann S; Grosskopf C; Shak S; Mougel D; Polu JM
Eur Respir J; 1996 Apr; 9(4):765-9. PubMed ID: 8726943
[TBL] [Abstract][Full Text] [Related]
4. Effect of a short course of rhDNase on cough and mucociliary clearance in patients with cystic fibrosis.
Robinson M; Hemming AL; Moriarty C; Eberl S; Bye PT
Pediatr Pulmonol; 2000 Jul; 30(1):16-24. PubMed ID: 10862158
[TBL] [Abstract][Full Text] [Related]
5. Impact of PEGylation on the mucolytic activity of recombinant human deoxyribonuclease I in cystic fibrosis sputum.
Guichard MJ; Kinoo D; Aubriot AS; Bauwens N; Gougué J; Vermeulen F; Lebecque P; Leal T; Vanbever R
Clin Sci (Lond); 2018 Jul; 132(13):1439-1452. PubMed ID: 29871879
[TBL] [Abstract][Full Text] [Related]
6. Improved clearability of cystic fibrosis sputum with dextran treatment in vitro.
Feng W; Garrett H; Speert DP; King M
Am J Respir Crit Care Med; 1998 Mar; 157(3 Pt 1):710-4. PubMed ID: 9517580
[TBL] [Abstract][Full Text] [Related]
7. Improvement of cystic fibrosis airway mucus transportability by recombinant human DNase is related to changes in phospholipid profile.
Zahm JM; Galabert C; Chaffin A; Chazalette JP; Grosskopf C; Puchelle E
Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 1):1779-84. PubMed ID: 9620905
[TBL] [Abstract][Full Text] [Related]
8. Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I.
King M; Dasgupta B; Tomkiewicz RP; Brown NE
Am J Respir Crit Care Med; 1997 Jul; 156(1):173-7. PubMed ID: 9230743
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human DNase (rhDNase) influences phospholipid composition, surface activity, rheology and consecutively clearance indices of cystic fibrosis sputum.
Griese M; App EM; Duroux A; Burkert A; Schams A
Pulm Pharmacol Ther; 1997; 10(1):21-7. PubMed ID: 9344829
[TBL] [Abstract][Full Text] [Related]
10. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis.
Shah PL; Scott SF; Knight RA; Marriott C; Ranasinha C; Hodson ME
Thorax; 1996 Feb; 51(2):119-25. PubMed ID: 8711640
[TBL] [Abstract][Full Text] [Related]
11. Aerosolized recombinant human DNase I for the treatment of cystic fibrosis.
Shak S
Chest; 1995 Feb; 107(2 Suppl):65S-70S. PubMed ID: 7842816
[TBL] [Abstract][Full Text] [Related]
12. Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis.
Laube BL; Auci RM; Shields DE; Christiansen DH; Lucas MK; Fuchs HJ; Rosenstein BJ
Am J Respir Crit Care Med; 1996 Feb; 153(2):752-60. PubMed ID: 8564129
[TBL] [Abstract][Full Text] [Related]
13. Reduction in viscoelasticity in cystic fibrosis sputum in vitro using combined treatment with nacystelyn and rhDNase.
Dasgupta B; King M
Pediatr Pulmonol; 1996 Sep; 22(3):161-6. PubMed ID: 8893254
[TBL] [Abstract][Full Text] [Related]
14. Improved activity of an actin-resistant DNase I variant on the cystic fibrosis airway secretions.
Zahm JM; Debordeaux C; Maurer C; Hubert D; Dusser D; Bonnet N; Lazarus RA; Puchelle E
Am J Respir Crit Care Med; 2001 Apr; 163(5):1153-7. PubMed ID: 11316652
[TBL] [Abstract][Full Text] [Related]
15. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis.
Hodson ME
Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S70-4. PubMed ID: 7881698
[TBL] [Abstract][Full Text] [Related]
16. Distearoyl phosphatidylglycerol liposomes improve surface and transport properties of CF mucus.
Girod de Bentzmann S; Pierrot D; Fuchey C; Zahm JM; Morançais JL; Puchelle E
Eur Respir J; 1993 Sep; 6(8):1156-61. PubMed ID: 8224130
[TBL] [Abstract][Full Text] [Related]
17. Effects of sputum oscillations and rhDNase in vitro: a combined approach to treat cystic fibrosis lung disease.
Dasgupta B; Brown NE; King M
Pediatr Pulmonol; 1998 Oct; 26(4):250-5. PubMed ID: 9811074
[TBL] [Abstract][Full Text] [Related]
18. Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability.
Wills PJ; Wodehouse T; Corkery K; Mallon K; Wilson R; Cole PJ
Am J Respir Crit Care Med; 1996 Aug; 154(2 Pt 1):413-7. PubMed ID: 8756815
[TBL] [Abstract][Full Text] [Related]
19. Physical and functional properties of airway secretions in cystic fibrosis--therapeutic approaches.
Puchelle E; de Bentzmann S; Zahm JM
Respiration; 1995; 62 Suppl 1():2-12. PubMed ID: 7792436
[TBL] [Abstract][Full Text] [Related]
20. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.
Fuchs HJ; Borowitz DS; Christiansen DH; Morris EM; Nash ML; Ramsey BW; Rosenstein BJ; Smith AL; Wohl ME
N Engl J Med; 1994 Sep; 331(10):637-42. PubMed ID: 7503821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
